Filtered By:
Condition: Hemorrhagic Stroke
Therapy: Thrombolytic Therapy

This page shows you your search results in order of relevance. This is page number 17.

Order by Relevance | Date

Total 340 results found since Jan 2013.

Efficacy and safety of intravenous thrombolysis with alteplase for treating acute ischemic stroke at different time windows: A protocol for systematic review and meta-analysis
Conclusions: This study will provide an evidence-based basis for the clinical efficacy of alteplase for treating AIS by thrombolytic therapy at different time windows. Ethics and dissemination: Private information from individuals will not be published. This systematic review also does not involve endangering participant rights. Ethical approval was not required. The results may be published in a peer-reviewed journal or disseminated at relevant conferences. OSF Registration number: DOI 10.17605 / OSF.IO / K7PHB
Source: Medicine - December 24, 2020 Category: Internal Medicine Tags: Research Article: Study Protocol Systematic Review Source Type: research

Different Scores Predict the Value of Hemorrhagic Transformation after Intravenous Thrombolysis in Patients with Acute Ischemic Stroke
CONCLUSION: The lower the ASPECTS score and the higher the DRAGON, SEDAN, and HAT scores, the higher the incidence of HT in AIS patients. The patient's age, atrial fibrillation, baseline NIHSS score, early signs of infarction on admission with head CT, time from onset to thrombolytic therapy, and thrombolytic drugs are all independent factors affecting HT in AIS patients. The scores of ASPECTS, DRAGON, SEDAN and HAT have certain value in predicting HT after intravenous thrombolysis in AIS patients, and the predicted value of ASPECTS score is the best.PMID:34721622 | PMC:PMC8553431 | DOI:10.1155/2021/2468052
Source: Evidence-based Complementary and Alternative Medicine - November 1, 2021 Category: Complementary Medicine Authors: Xiaozan Chang Xiaoxi Zhang Guanglin Zhang Source Type: research

Efficacy and safety of rt-PA intravenous thrombolysis in patients with wake-up stroke: A meta-analysis
Background : Recombinant tissue plasminogen activator (rt-PA) is one of the most effective therapies for patients with acute ischemic stroke. However, wake-up stroke (WUS) is typically excluded from intravenous thrombolytic therapy because of the unclear time of symptom onset. Therefore, we aimed to assess the efficacy and safety of rt-PA intravenous thrombolysis in patients with WUS by meta-analysis. Methods : We completed a systematic literature search of PubMed, Embase, the Cochrane Library, and SinoMed and included relevant studies of WUS patients covering rt-PA thrombolysis and nonthrombolysis (published fr...
Source: Medicine - February 18, 2022 Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research

An Optimal Animal Model of Ischemic Stroke Established by Digital Subtraction Angiography-Guided Autologous Thrombi in Cynomolgus Monkeys
ConclusionOur study may provide an optimal non-human primate model for an in-depth study of the pathogenesis and treatment of focal cerebral ischemia.
Source: Frontiers in Neurology - April 25, 2022 Category: Neurology Source Type: research

Safety and Efficacy of Tirofiban During Intravenous Thrombolysis Bridging to Mechanical Thrombectomy for Acute Ischemic Stroke Patients: A Meta-Analysis
ConclusionThe use of tirofiban during IVT bridging mechanical thrombectomy for AIS does not increase the risk of sICH and ICH in patients and reduces the risk of postoperative re-occlusion and mortality in patients within 3 months. However, this result needs to be further confirmed by additional large-sample, multicenter, prospective randomized controlled trials.Systematic Review Registrationhttp://www.crd.york.ac.uk/PROSPERO/, identifier: CRD42022297441.
Source: Frontiers in Neurology - April 29, 2022 Category: Neurology Source Type: research

Hemorrhagic Transformation during Thrombolytic Therapy and Reperfusion: Effects of Age, Blood Pressure, and Matrix Metalloproteinases
Background: Despite the increasing use of thrombolytic therapy for acute ischemic stroke, hemorrhagic transformation remains a significant complication. Transformation appears to occur more frequently with age, diabetes, and hypertension, but clinical data are mixed. In addition to risk factors, matrix metalloproteinase expression mediates hemorrhage. We sought to test the effects of age, hypertension, and matrix metalloproteinases during recombinant tissue plasminogen activator (rt-PA) treatment in a standard model of filament occlusion of the middle cerebral artery.Methods: We compared young and aged rats who were geneti...
Source: Journal of Stroke and Cerebrovascular Diseases - March 4, 2013 Category: Neurology Authors: Patrick D. Lyden Tags: Original Articles Source Type: research

Presentation, therapy and outcome of patients with ischemic stroke under new oral anticoagulants.
CONCLUSIONS: Little is known about ischemic strokes under NOAC. To increase the knowledge, the data of 469 ischemic strokes which occurred in NOAC-investigating trials should be analyzed. Furthermore ischemic and bleeding events under NOAC outside clinical trials should be reported. An international registry, independent from the pharmaceutical industry for collecting these informations is desirable. PMID: 24821640 [PubMed - as supplied by publisher]
Source: Neurologia i Neurochirurgia Polska - March 1, 2014 Category: Neurology Authors: Stöllberger C, Finsterer J Tags: Neurol Neurochir Pol Source Type: research

Validation assessment of risk tools to predict outcome after thrombolytic therapy for acute ischemic stroke
Thrombolytic therapy generally improves clinical outcome after acute ischemic stroke, but the decision to administer thrombolytics may be challenging because of hemorrhagic complications and poor response in some patients [1–4]. Many models for risk stratification of thrombolytic treatment have been developed to support the clinician in this complex decision-making process.
Source: Clinical Neurology and Neurosurgery - August 14, 2014 Category: Neurosurgery Authors: Robbert-Jan Van Hooff, Koenraad Nieboer, Ann De Smedt, Maarten Moens, Peter Paul De Deyn, Jacques De Keyser, Raf Brouns Source Type: research

Modest Association between the Discharge Modified Rankin Scale Score and Symptomatic Intracerebral Hemorrhage after Intravenous Thrombolysis
Thirty- and 90-day modified Rankin Scale (mRS) scores are used to monitor adverse outcome or symptomatic intracerebral hemorrhage (sICH) in ischemic stroke patients after intravenous (IV) thrombolytic therapy. Discharge mRS scores are more readily available and could serve as a proxy for 30- or 90-day mRS data. Our goal was to evaluate agreement between the discharge mRS score and sICH. Additionally, we tested for correlations between the discharge mRS score and 8 clinical scores developed to predict sICH or adverse outcomes based on 90-day mRS data.
Source: Journal of Stroke and Cerebrovascular Diseases - December 22, 2014 Category: Neurology Authors: David Asuzu, Karin Nystrom, Hardik Amin, Joseph Schindler, Charles Wira, David Greer, Nai Fang Chi, Janet Halliday, Kevin N. Sheth Source Type: research

Symptomatic intracranial hemorrhage in the ALIAS Multicenter Trial: relationship to endovascular thrombolytic therapy
ConclusionsEndovascular thrombolysis was the major factor predisposing to symptomatic intracranial hemorrhage, and albumin contributed to this predisposition. The latter may be mediated by albumin's influence on platelet aggregation or collateral perfusion.
Source: International Journal of Stroke - March 22, 2015 Category: Neurology Authors: Myron D. Ginsberg, Michael D. Hill Tags: Research Source Type: research

Lack Of Tafi Increases Brain Damage And Microparticle Generation After Thrombolytic Therapy In Ischemic Stroke
Thrombin-activatable fibrinolysis inhibitor (TAFI) plays an important role in coagulation and fibrinolysis. Whereas TAFI deficiency may lead to a haemorrhagic tendency, data from TAFI knockout mice (TAFI−/−) are controversial and no differences have been reported in these animals after ischemic stroke. There are also no data regarding the role of circulating microparticles (MPs) in TAFI−/−.
Source: Thrombosis Research - June 10, 2015 Category: Hematology Authors: Orbe J, Alexandru N, Roncal C, Belzunce M, Bibiot P, Rodriguez JA, Meijers JCM, Georgescu A, Paramo JA Source Type: research

Angiogram-negative subarachnoid hemorrhage after intravenous thrombolysis in a patient with acute ischemic stroke
We describe a patient with SAH immediately after thrombolytic therapy.
Source: Journal of Stroke and Cerebrovascular Diseases - March 18, 2017 Category: Neurology Authors: Kyung-Hee Cho, Jae-Gyum Kim, Sungwook Yu, Kyung-Hee Cho Source Type: research

Endovascular mechanical thrombectomy for cerebral venous sinus thrombosis: a systematic review
Conclusions EMT is an effective salvage therapy for refractory CVST, with a reasonable safety profile. Chemical thrombolysis, in conjunction with EMT, did not appear to result in additional harm or benefit. Further analysis is warranted to determine predictors of success after EMT for CVST.
Source: Journal of NeuroInterventional Surgery - October 13, 2017 Category: Neurosurgery Authors: Ilyas, A., Chen, C.-J., Raper, D. M., Ding, D., Buell, T., Mastorakos, P., Liu, K. C. Tags: Ischemic stroke Source Type: research

LDL receptor blockade reduces mortality in a mouse model of ischaemic stroke without improving tissue-type plasminogen activator-induced brain haemorrhage: towards pre-clinical simulation of symptomatic ICH
Symptomatic intracerebral haemorrhage (sICH) following tissue-type plasminogen activator (rt-PA) administration is the most feared and lethal complication of thrombolytic therapy for ischaemic stroke, creating...
Source: Cerebrospinal Fluid Research - November 21, 2017 Category: Neurology Authors: Be ’eri Niego, Brad R. S. Broughton, Heidi Ho, Christopher G. Sobey and Robert L. Medcalf Tags: Research Source Type: research

Comparative Analysis on Low- and Standard-Dose Regimes of Alteplase Thrombolytic Therapy for Acute Ischemic Stroke: Efficacy and Safety
Conclusion: The efficacy of low-dose alteplase intravenous thrombolytic therapy for AIS was equivalent to the standard-dose regimen but with higher safety.Eur Neurol 2018;79:68 –73
Source: European Neurology - December 14, 2017 Category: Neurology Source Type: research